Primaquine toxicity forestalls effective therapeutic management of the endemic malarias

International Journal for Parasitology

Volumn 42, Issue 12, 2012, Pages 1049-1054

  Baird, J Kevin ^a,b  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chemotherapy; Elimination; Endemic; Malaria; Practice; Strategy

Indexed keywords

ARTEMISININ; CHLOROQUINE; MEPACRINE; PAMAQUINE; PRIMAQUINE; TAFENOQUINE;

ACCESSIBILITY; DISEASE CONTROL; DISEASE TRANSMISSION; DISEASE TREATMENT; HEALTH GEOGRAPHY; MALARIA; MEDICINE; TOXICITY TEST;

ACUTE DISEASE; ANTIMALARIAL DRUG RESISTANCE; APICOMPLEXAN LIFE CYCLE STAGE; BLOOD TOXICITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDEMIC DISEASE; ERADICATION THERAPY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMAN; INFECTION PREVENTION; MALARIA; MALARIA FALCIPARUM; NONHUMAN; OPTIMAL DRUG DOSE; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; RELAPSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT PLANNING;

ANTIMALARIALS; ENDEMIC DISEASES; HUMANS; MALARIA; PRIMAQUINE;

EID: 84869885390     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.06.006     Document Type: Review

References (47)

1. Alving A.S., Arnold J., Hockwald R.S., Clayman C.B., Dern R.J., Beutler E., Flanagan C.L. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J. Lab. Clin. Med. 1955, 45:286-295.
2. Alving A.S., Johnson C.F., Tarlov A.R., Brewer G.J., Kellermeyer R.W., Carson P.E. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull. WHO 1960, 22:621-631.
3. Baird J.K., Hoffman S.L. Primaquine therapy for malaria. Clin. Infect. Dis. 2004, 39:1336-1345.
4. Baird J.K. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob. Agents Chemother. 2011, 55:1827-1830.
5. Baird J.K., Surjadjaja C. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 2011, 27:11-16.
6. Baird J.K. Elimination therapy for the endemic malarias. Curr. Inf. Dis. Rep. 2012, 14:227-237.
7. Barrett O., Skrzypek G., Datel W., Goldstein J.D. Malaria imported to the United States from Vietnam: chemoprophylaxis evaluated in returning soldiers. Am. J. Trop. Med. Hyg. 1969, 18:495-499.
8. Beutler E. Glucose-6-phosphate dehydrogenase deficiency. Blood 1994, 84:3613-3636.
9. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 2008, 111:16-24.
10. Burgess R.W., Bray R.S. Effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum. Bull. WHO 1961, 24:451-456.
11. Carson P.E., Flanagan C.L., Ickes C.E., Alving A.S. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956, 124:484-485.
12. Chattopadhyay R., Velmurugan S., Chakiath C., Andrews D.L., Milhous W., Barnwell J.W., Collins W.E., Hoffman S.L. Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS One 2010, 5:e14275.
13. Coatney G.R. Pitfalls in a discovery: the chronicle of chloroquine. Am. J. Trop. Med. Hyg. 1963, 12:121-128.
14. Coatney G.R., Collins W.E., Warren M., Contacos P.G. The Primate Malarias 1971, US Government Printing Office, Washington, DC.
15. Crockett M., Kain K.C. Tafenoquine: a promising new antimalarial agent. Expert Opin. Investig. Drugs 2007, 16:705-715.
16. Cui L., Su X.Z. Discovery, mechanisms of action, and combination therapy of artemisinin. Expert Rev. Anti Infect. Ther. 2009, 7:999-1013.
17. Davidson D.E., Ager A.L., Brown J.L., Chapple F.E., Whitmire R.E., Rossan R.N. New tissue schizontocidal antimalarial drugs. Bull. World Health Org. 1981, 59:463-479.
18. Douglas N.M., Nosten F., Ashley E.A., Phaiphun L., van Vugt M., Singhasivanon P., White N.J., Price R.N. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin. Inf. Dis. 2011, 52:612-620.
19. Dow G.S., Gattayacamin M., Hansukjariya P., Imerbsin R., Komcharoen S., Sattabongkot J., Kyle D., Milhous W., Cozens S., Kenworthy D., Miller A., Veazey J., Ohrt C. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected rhesus monkeys (Macaca mulatta). Malaria J. 2011, 10:212.
20. Field J.W. Notes on the chemotherapy of malaria. Bull. Inst. Med. Res. Fed. Malay States 1938, 2:63-79.
21. George G.N., Sears D.A., McCurdy P.R., Conrad M.E. Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G6PD deficient subjects. J. Lab. Clin. Med. 1967, 70:80-93.
22. Gething P.W., Patil A.P., Smith D.L., Guerra C.A., Elyazar I.R., Johnston G.L., Tatem A.J., Hay S.I. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malaria J. 2011, 10:378.
23. Gosling R.D., Cairns M.E., Chico R.M., Chandramohan D. Intermittent preventive treatment against malaria: an update. Expert Rev. Anti Infect. Ther. 2010, 8:589-606.
24. Greenwood D. Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war. J. Antimicrob. Chemother. 1995, 36:857-872.
25. Guerra C., Howes R.E., Patil A.P., Gething P.W., Van Boekel T.P., Temperley W.H., Kabaria C.W., Tatem A.J., Mahh B.H., Elyazar I.R., Baird J.K., Snow R.W., Hay S.I. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 2010, 4:e774.
26. Harris I., Sharrock W., Bain L.W., Gray K.A., Bobogare A., Boaz L., Lilley K., Krause D., Vallely A., Johnson M.L., Gatton M.L., Shanks G.D., Cheng Q. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting for Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malaria J. 2010, 9:254.
27. Mueller I., Widmer S., Michel D., Maraga S., McNamara D.T., Kiniboro B., Sie A., Smith T.A., Zimmerman P.A. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malaria J. 2009, 8:41.
28. Ockenhouse C.F., Magill A., Smith D., Milhous W. History of US military contributions to the study of malaria. Mil. Med. 2005, 170(suppl. 1):12-16.
29. Pannacciulli I., Tizianello A., Ajmar F., Salvidio E. The course of experimentally hemolytic anemia in a primaquine-sensitive Caucasian: a case study. Blood 1965, 25:92-95.
30. Peters W. Chemotherapy and Drug Resistance 1987, vol. 2. Academic Press, London, p. 583 (1100 pp). second ed.
31. Rieckmann K.H., McNamara J.V., Frischer H., Stokert T.A., Carson P.E., Powell R.D. Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyramethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull. World Heath Org. 1968, 38:625-632.
32. Rieckmann K.H., McNamara J.V., Kass L., Powell R.D. Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum. Mil. Med. 1969, 134(10):802-819. (special issue).
33. Rosenberg R. Plasmodium vivax in Africa: hidden in plain sight?. Trends Parasitol. 2007, 23:193-196.
34. Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem. Med. Chem. 2007, 2:944-986.
35. Shannon J.A. Chemotherapy of malaria. Bull. NY. Acad. Med. 1946, 22:345-357.
36. Shekalaghe S., Drakeley C., Gosling R., Ndaro A., van Meegeren M., Enevold A., Alifrangis M., Mosha F., Sauerwein R., Bousema T. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and Artesunate. PLoS One 2007, 2:e1023.
37. Shekalaghe S., ter Braak R., Daou M., Kavishe R., van den Bijlaardt W., van den Bosch S., Koenderink J.B., Luty A.J., Whitty C.J., Drakeley C., Sauerwein R.W., Bousema T. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artimisinin is not restricted to glucose-6-phosphate dehydrogenase deficient (A-) individuals. Antimicrob. Agents Chemother. 2010, 54:1762-1768.
38. Slater L.B. War and Disease: Biomedical Research on Malaria in the 20th Century. Critical Issues in Health and Medicine Series 2009, Rutgers University Press, New Brunswick, NJ.
39. Steenkeste N., Rogers W.O., Okell L., Jeanne I., Incardona S., Duval L., Chy S., Hewitt S., Chou M., Socheat D., Babin F.X., Ariey F., Rogier C. Sub-microscopic malaria cases and mixed infection in a remote area of high malaria endemicity in Rattanakiri province, Cambodia: implications for elimination. Malaria J. 2010, 9:108.
40. Surgeon General of the United States The drug treatment of malaria, suppressive and clinical. Circular letter no. 153. J. Am. Med. Assoc. 1943, 123:205-208.
41. Sweeney A.W. Wartime research on malaria chemotherapy. Parassitologia 2000, 42:33-45.
42. Wellems T.E., Miller L.H. Two worlds of malaria. New Engl. J. Med. 2003, 349:1496-1498.
43. Wells T.N., Burrows J.N., Baird J.K. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010, 26:145-151.
44. Westenberger S.J., McClean C.M., Chattopadhyay R., Dharia N.V., Carlton J.M., Barnwell J.W., Collins W.E., Hoffman S.L., Zhou Y., Vinetz J.M., Winzeler E.A. A systems-based analysis of Plasmodium vivax lifecycle transcription from human to mosquito. PLoS Negl. Trop. Dis. 2010, 4:e653.
45. White N. Antimalarial drug resistance and combination therapy. Phil. Trans. Roy. Soc. Lond. 1999, 354:739-749.
46. World Health Organization Guidelines for the Treatment of Malaria 2010, WHO, Geneva, Switzerland. second ed.
47. World Health Organization, 2011. Consideration of mass drug administration for the containment of artemisinin-resistant malaria in the greater Mekong subregion. Report of a consensus meeting, 27-28 September 2010. WHO, Geneva, Switzerland.